2-(N-butylanilino)ethanol | 3046-94-4

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(N-butylanilino)ethanol
• 英文别名: 2-(N-tert-butylanilino)ethanol
• CAS: 3046-94-4
• 化学式: C₁₂H₁₉NO
• 分子量: 193.289
• InChiKey: RJKVYPXVNOBMCH-UHFFFAOYSA-N

物化性质

• 沸点：
  143-145 °C(Press: 1.5 Torr)
• 密度：
  1.012±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090

反应信息

• 作为产物：
  描述：

  lithium di-tertbutyl cuprate 、 N-苯基乙醇胺 在 氧气 作用下， 生成 2-(N-butylanilino)ethanol
  参考文献：
  名称：

  Novel N-alkylation of amines with organocopper reagents

  摘要：

  DOI：

  10.1021/jo01301a048

文献信息

• NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Yoshida Tomohiro

  公开号：US20100228026A1

  公开（公告）日：2010-09-09

  The invention provides a sulfonyl malonamide derivative, or a pharmacologically acceptable salt thereof or a solvate thereof, that has therapeutic and/or preventive effect(s) on various diseases due to its agonist action at AT 2 receptor, and is useful as a pharmaceutical agent for the treatment and/or prevention of diseases involving the renin-angiotensin-aldosterone system (RAAS).

  该发明提供了一种磺酰基马隆酰胺衍生物，或其药理学上可接受的盐或溶剂，由于其在AT2受体上的激动剂作用，对各种疾病具有治疗和/或预防作用，并且作为用于治疗和/或预防涉及肾素-血管紧张素-醛固酮系统（RAAS）疾病的药物剂形具有用处。
• Lipid nanoparticle composition
  申请人：Suzhou Abogen Biosciences Co., Ltd.

  公开号：US11472766B2

  公开（公告）日：2022-10-18

  Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination.

  本文提供的脂质可与其他脂质成分（如中性脂质、胆固醇和聚合物共轭脂质）结合使用，形成脂质纳米粒子，用于递送治疗剂（如核酸分子），以达到治疗或预防目的，包括接种疫苗。
• Methods for predicting the biological, chemical, and physical properties of molecules from their spectral properties
  申请人：The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services

  公开号：US20040220749A1

  公开（公告）日：2004-11-04

  Methods are disclosed for establishing a quantitative relationship between spectral properties of molecules and a biological, chemical, or physical endpoint of the molecules. Spectral data including data from nuclear magnetic resonance, mass spectrometric, infrared, and ultraviolet-visible techniques are used along with endpoint data to train a pattern-recognition program. The training yields a spectral data-activity relationship that may be used to predict the endpoint value of a molecule from its spectral data alone. Methods for rapidly screening isolated compounds or mixtures of compounds based upon their spectral data are included.

  本文公开了在分子的光谱特性与分子的生物、化学或物理终点之间建立定量关系的方法。光谱数据包括来自核磁共振、质谱、红外和紫外可见光技术的数据，这些数据与终点数据一起用于训练模式识别程序。训练产生的光谱数据与活性之间的关系，可用于仅从光谱数据预测分子的终点值。此外，还包括根据光谱数据快速筛选分离化合物或化合物混合物的方法。
• MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS
  申请人：NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER

  公开号：US20170014419A1

  公开（公告）日：2017-01-19

  Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.
• LIPID NANOPARTICLE COMPOSITION
  申请人：Suzhou Abogen Biosciences Co., Ltd.

  公开号：US20220153686A1

  公开（公告）日：2022-05-19

  Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination.